Clinical Trials Browser

Withdrawn × Specimen Handling × Myeloid × Clear all

NCT05823480 2024-09-19

Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

Phase 1 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute